论文部分内容阅读
目的 研究肝癌切除术后 ,肝动脉灌注LAK细胞 /白介素Ⅱ配合化学药物栓塞治疗的价值。方法 肝癌切除者 5 0例 ,随机分为两组。 2 5例为观察组 ,肝癌切除术后 ,肝动脉灌注LAK细胞 /白介素Ⅱ配合化学药物栓塞治疗 ;单纯肝癌切除 2 5例为对照组。对两组病例 1年、2年的肝内复发率和生存率差别分别作 χ2 检验。结果 观察组 1年、2年的肝内复发率 4% (1/2 5 )、16 % (4 /2 5 )较对照组 32 % (8/2 5 )、44 % (11/2 5 )降低 (χ2 值分别为 4 88、4 6 7,P值均小于 0 0 5 ) ;观察组 1年、2年的生存率为 96 % (2 4/2 5 )、80 % (2 0 /2 5 )较对照组 6 8% (17/2 5 )、5 2 % (13/2 5 )提高 (χ2 值分别为 4 88、4 37,P值均小于 0 0 5 )。结论 肝癌切除术后 ,肝动脉灌注的LAK细胞 /白介素Ⅱ与某些化学药物协同杀灭残留癌细胞 ,并且改善宿主的抗肿瘤免疫状态 ;肝动脉栓塞又进一步使残癌组织缺血坏死。肝癌切除术后 ,肝动脉灌注LAK细胞 /白介素Ⅱ配合化学药物栓塞治疗是很有价值的。
Objective To study the value of hepatic artery perfusion LAK cells/interleukin II combined with chemoembolization after liver cancer resection. Methods A total of 50 patients with hepatocellular carcinoma were randomly divided into two groups. Twenty-five patients in the observation group were treated with hepatic artery perfusion with LAK cells/interleukin II combined with chemotherapy embolization after hepatectomy. Twenty-five patients with hepatocellular carcinoma resection were served as control group. The difference between the intra-hepatic recurrence rate and the survival rate of the two groups of patients at 1 year and 2 years was tested separately. Results The intra-hepatic recurrence rate of the observation group was 4% (1/2 5), 16% (4/25), and 32% (8/2 5), 44% (11/2 5) of the control group at 1 year and 2 years. Decrease (χ2 values were 488 and 467, respectively; P values were all less than 0 05); the 1-year and 2-year survival rates in the observation group were 96% (2 4/2 5 ), 80% (2 0 /2). 5) Compared with the control group, 68% (17/2 5) and 5 2% (13/2 5) increased (χ 2 values were 4 88 and 4 37, respectively; P values were less than 0 05). Conclusion After hepatectomy, hepatic artery perfusion of LAK cells/IL-II cooperates with certain chemical drugs to kill residual cancer cells and improve the host’s anti-tumor immune status. Hepatic artery embolization further promotes ischemic necrosis of residual cancer tissue. After liver cancer resection, hepatic arterial infusion of LAK cells / interleukin II with chemical embolization therapy is very valuable.